483
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA 483, Jan 25, 2017
Record Details
An FDA inspection of Celgene Corporation's headquarters in Summit, NJ, revealed significant deficiencies in adverse drug experience reporting. The firm failed to report numerous serious and unexpected adverse drug experiences to the FDA within the required 15 calendar days. This included approximately 724 initial and follow-up reports submitted late between August 2015 and December 2016, with some delays extending over several years.
View Company Profile
ID · d9ab1e53-7ce9-4a8c-b38e-01f5e565a0ed
Other documents for Bristol-Myers Squibb Company
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.